Myxoid Liposarcoma – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Myxoid Liposarcoma – Drugs In Development, 2024 report and make more profitable business decisions.
A myxoid liposarcoma is a malignant adipose tissue neoplasm of myxoid appearance histologically. Myxoid/round cell liposarcoma, or MRCLS, is one of several types of liposarcoma. Liposarcoma is a rare cancer that grows in the cells that store fat in the body. MRCLS usually grows in the arms and legs. These tumors grow slowly, and they can spread to other parts of the body.
The Myxoid Liposarcoma drugs in development market research report provide comprehensive information on the therapeutics under development for Myxoid Liposarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myxoid Liposarcoma and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Myxoid Liposarcoma | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 17 molecules, with 16 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Myxoid Liposarcoma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Myxoid Liposarcoma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Myxoid Liposarcoma treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Adaptimmune Therapeutics PlcANTUREC Pharmaceuticals GmbH
AVM Biotechnology LLC
Daiichi Sankyo Co Ltd
Immutep Ltd
Incyte Corp
Jiangsu Hengrui Medicine Co Ltd
Kronos Bio Inc
Lixte Biotechnology Holdings Inc
Lyell Immunopharma Inc
Merck & Co Inc
Pfizer Inc
Pharma Mar SA
Philogen SpA
SOTIO Biotech AS
Syena
United Immunity Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Myxoid Liposarcoma reports